Back to Search
Start Over
A phase II study of vibecotamab, a CD3-CD123 bispecific T-cell engaging antibody, for MRD-positive AML and MDS after hypomethylating agent failure.
- Source :
- Journal of Clinical Oncology; 2023 Supplement 16, Vol. 41, pTPS7076-TPS7076, 1p
- Publication Year :
- 2023
Details
- Language :
- English
- ISSN :
- 0732183X
- Volume :
- 41
- Database :
- Supplemental Index
- Journal :
- Journal of Clinical Oncology
- Publication Type :
- Academic Journal
- Accession number :
- 164018360
- Full Text :
- https://doi.org/10.1200/JCO.2023.41.16_suppl.TPS7076